Peringatan Keamanan

Ceftazidime overdosage has occurred in patients with renal failure. Reactions included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma. Patients who receive an acute overdosage should be carefully observed and given supportive treatment. In the presence of renal insufficiency, hemodialysis or peritoneal dialysis may aid in the removal of ceftazidime from the body.L32935

Ceftazidime

DB00438

small molecule approved

Deskripsi

Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs).A232920 ?-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death.A232920, A232925, A232930 Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.L32935

Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-?-lactam ?-lactamase inhibitor avibactam to treat a variety of bacterial infections.L32935, L32940

Struktur Molekul 2D

Berat 546.576
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Ceftazidime has an elimination half-life of 1.5-2.8 hours in healthy subjects.[A232935, L32935] As ceftazidime is primarily renally excreted, its half-life is significantly prolonged in patients with renal impairment.[L32935] In patients with creatinine clearance < 12 mL/min, the half-life is prolonged to between 14 and 30 hours.[A232935]
Volume Distribusi Ceftazidime has a volume of distribution of 15-20 L.[A232935]
Klirens (Clearance) The mean renal clearance of ceftazidime in healthy subjects ranges from 72 to 141 mL/min while the calculated plasma clearance is approximately 115 mL/min.[A232935, L32935]

Absorpsi

Ceftazidime administered intravenously in healthy males produced mean Cmax values of between 42 and 170 ?g/mL for doses between 500 mg and 2 g, and are reached immediately following the end of the infusion period.L32935 The Cmax for 1 g of ceftazidime administered intramuscularly is attained approximately one hour following injection and is between 37 and 43 mg/L.A232935 Following intramuscular administration of 500 mg and 1 g of ceftazidime, the serum concentration remained above 4 ?g/mL for six and eight hours, respectively.L32935 Ceftazidime Cmax and AUC show linear proportionality to the dose over the therapeutic range.A232935, L32935 In individuals with normal renal function, ceftazidime given intravenously every eight hours for 10 days as either 1 or 2 g doses showed no accumulation.L32935

Metabolisme

Ceftazidime is not appreciably metabolized.A232935

Rute Eliminasi

Approximately 80% to 90% of an intramuscular or intravenous dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. When administered intravenously, 50% of the dose appears in the urine within two hours, with another 32% of the dose appearing by eight hours post-administration.L32935

Interaksi Obat

846 Data
Chloramphenicol The therapeutic efficacy of Ceftazidime can be decreased when used in combination with Chloramphenicol.
Probenecid The serum concentration of Ceftazidime can be increased when it is combined with Probenecid.
Foscarnet The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceftazidime.
Tenofovir disoproxil Ceftazidime may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ceftazidime.
Tenofovir Ceftazidime may increase the nephrotoxic activities of Tenofovir.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Ceftazidime.
Etacrynic acid The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Etacrynic acid.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Hydrochlorothiazide.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftazidime.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Ceftazidime.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Ceftazidime.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftazidime.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Ceftazidime.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Ceftazidime.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Ceftazidime.
Cidofovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ceftazidime.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Ceftazidime.
Piroxicam The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Piroxicam.
Methotrexate The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Methotrexate.
Cephalexin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cephalexin.
Valaciclovir The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Valaciclovir.
Flurbiprofen The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Flurbiprofen.
Etodolac The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Etodolac.
Acyclovir The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Acyclovir.
Cefaclor The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefaclor.
Diflunisal The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Diflunisal.
Bumetanide The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Bumetanide.
Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Meclofenamic acid.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Acetylsalicylic acid.
Carboplatin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Carboplatin.
Oxaprozin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Oxaprozin.
Ketoprofen The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ketoprofen.
Ibuprofen The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ibuprofen.
Cefadroxil The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefadroxil.
Ceftriaxone The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ceftriaxone.
Cefotetan The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefotetan.
Cefradine The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefradine.
Ceftibuten The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ceftibuten.
Aceclofenac The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Aceclofenac.
Benzydamine The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Benzydamine.
Dexketoprofen The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Dexketoprofen.
Propacetamol The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Propacetamol.
Cefroxadine The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefroxadine.
Alclofenac The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Alclofenac.
Loracarbef The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Loracarbef.
Cefalotin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefalotin.
Nabumetone The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Nabumetone.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ketorolac.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Tenoxicam.
Celecoxib The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Celecoxib.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefotaxime.
Tolmetin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Tolmetin.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Rofecoxib.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Fenoprofen.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Valdecoxib.
Diclofenac The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Diclofenac.
Sulindac The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Sulindac.
Bacitracin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Bacitracin.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Amphotericin B.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cephaloglycin.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Adefovir dipivoxil.
Pentamidine The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Pentamidine.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Mefenamic acid.
Naproxen The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Naproxen.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Sulfasalazine.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Phenylbutazone.
Meloxicam The risk or severity of methemoglobinemia can be increased when Ceftazidime is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Carprofen.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Tacrolimus.
Ceforanide The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ceforanide.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Salicylic acid.
Balsalazide The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Balsalazide.
Cefditoren The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefditoren.
Atazanavir The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Atazanavir.
Colistimethate The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Colistimethate.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefuroxime.
Cefapirin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefapirin.
Cefprozil The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefprozil.
Olsalazine The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Olsalazine.
Lumiracoxib The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Lumiracoxib.
Cefamandole The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefamandole.
Cefazolin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefazolin.
Cefonicid The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefonicid.
Cefoperazone The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefoperazone.
Cefoxitin The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefoxitin.
Ceftizoxime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ceftizoxime.
Magnesium salicylate The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Magnesium salicylate.
Salsalate The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Salsalate.
Choline magnesium trisalicylate The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Choline magnesium trisalicylate.
Cefepime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefepime.
Cefacetrile The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefacetrile.
Cefpodoxime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefpodoxime.
Antrafenine The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Antrafenine.
Aminophenazone The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Aminophenazone.
Antipyrine The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Antipyrine.
Tiaprofenic acid The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Tiaprofenic acid.
Lopinavir The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Lopinavir.
Etoricoxib The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Etoricoxib.

Target Protein

Peptidoglycan synthase FtsI ftsI
Penicillin-binding protein 1A mrcA
Penicillin-binding protein 1B mrcB
Penicillin-binding protein 2 mrdA
Beta-lactamase Toho-1 bla

Referensi & Sumber

Synthesis reference: Ronald C. Browning, Melvin G. Pleiss, Jr., "Crystallization process for ceftazidime derivative." U.S. Patent US4659813, issued May, 1982.
Artikel (PubMed)
  • PMID: 31747090
    Fisher JF, Mobashery S: Constructing and deconstructing the bacterial cell wall. Protein Sci. 2020 Mar;29(3):629-646. doi: 10.1002/pro.3737. Epub 2019 Nov 20.
  • PMID: 27329032
    Bush K, Bradford PA: beta-Lactams and beta-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med. 2016 Aug 1;6(8). pii: cshperspect.a025247. doi: 10.1101/cshperspect.a025247.
  • PMID: 33106266
    Sayed ARM, Shah NR, Basso KB, Kamat M, Jiao Y, Moya B, Sutaria DS, Lang Y, Tao X, Liu W, Shin E, Zhou J, Werkman C, Louie A, Drusano GL, Bulitta JB: First Penicillin-Binding Protein Occupancy Patterns for 15 beta-Lactams and beta-Lactamase Inhibitors in Mycobacterium abscessus. Antimicrob Agents Chemother. 2020 Dec 16;65(1). pii: AAC.01956-20. doi: 10.1128/AAC.01956-20. Print 2020 Dec 16.
  • PMID: 3884319
    Richards DM, Brogden RN: Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Feb;29(2):105-61. doi: 10.2165/00003495-198529020-00002.
  • PMID: 6413485
    Hayes MV, Orr DC: Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983 Aug;12(2):119-26.
  • PMID: 18250190
    Davies TA, Shang W, Bush K, Flamm RK: Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008 Apr;52(4):1510-2. doi: 10.1128/AAC.01529-07. Epub 2008 Feb 4.
  • PMID: 25561334
    Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA: Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 Mar;59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5.
  • PMID: 29712652
    Sutaria DS, Moya B, Green KB, Kim TH, Tao X, Jiao Y, Louie A, Drusano GL, Bulitta JB: First Penicillin-Binding Protein Occupancy Patterns of beta-Lactams and beta-Lactamase Inhibitors in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 May 25;62(6). pii: AAC.00282-18. doi: 10.1128/AAC.00282-18. Print 2018 Jun.
Menampilkan 8 dari 11 artikel.

Contoh Produk & Brand

Produk: 83 • International brands: 5
Produk
  • Avycaz
    Powder, for solution • - • Intravenous • US • Approved
  • Ceftazidime
    Injection, powder, for solution • 200 mg/1mL • Intravenous • US • Generic • Approved
  • Ceftazidime
    Injection, powder, for solution • 500 mg/1 • Intramuscular; Intravenous • US • Generic • Approved
  • Ceftazidime
    Injection, powder, for solution • 1 g/1 • Intramuscular; Intravenous • US • Generic • Approved
  • Ceftazidime
    Injection, powder, for solution • 2 g/1 • Intravenous • US • Generic • Approved
  • Ceftazidime
    Injection, powder, for solution • 500 mg/1 • Intramuscular; Intravenous • US • Generic • Approved
  • Ceftazidime
    Injection, powder, for solution • 1 g/1 • Intramuscular; Intravenous • US • Generic • Approved
  • Ceftazidime
    Injection, powder, for solution • 2 g/1 • Intravenous • US • Generic • Approved
Menampilkan 8 dari 83 produk.
International Brands
  • Cefzim — Pharco B International
  • Ceptaz
  • Fortum — GlaxoSmithKline
  • Tazidime
  • Veltadim — Novell

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul